Fixing The Weak Links In The Cell Therapy Manufacturing Chain: Processes, People, And Partnerships

The cell and gene therapy industry can move faster by shoring up its weakest links. Q&A with GE Healthcare’s Phil Vanek about how to do it.

A version of this podcast interview was originally published in Cell and Gene Therapy Insights on April 30, 2018. Vanek P. Fixing the weak links in the cell therapy manufacturing chain: processes, people and partnerships. Cell Gene Therapy Insights 2018; 4(4), 309-316. DOI: 10.18609/cgti.2018.031.